G0429 Insurance Policy Changes

HCPCS G0429 is officially defined as "Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)." HCPCS G0429 is referenced in 5 tracked payer policy changes from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0429 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.